A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL

NCT01203930 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Lymphoma (SLL)

Interventions

DRUG: Idelalisib
DRUG: Rituximab

Sponsor

Gilead Sciences